Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01763164
Recruitment Status : Active, not recruiting
First Posted : January 8, 2013
Last Update Posted : March 21, 2018
Information provided by (Responsible Party):
Array BioPharma